Patent ID: 7964354
Filing Date: 2011-06-21
Classification: C12Q

Abstract:
1. A method of assessing the activity of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide, 3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-1,1-dimethyl-urea, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline or N-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-4-trifluoromethoxybenzamide in a patient treated with said immunomodulatory compounds, comprising: a. obtaining a biological sample from said patient before and after the treatment; and b. measuring the level of miR-130a, miR-146b, miR-143, miR-145, miR-99b, miR-125a, miR-204, miR-424 or miR-503 in said biological samples; wherein an increased level of one or more of the miRNAs indicates the activity of said immunomodulatory compounds.